BASICS OF PRP THERAPY

David Greene, MD, MBA R3 Medical Training



OUTLINE

What it is.

What's in it.

Single vs. Double Spin.

Controversy

ndications/Research





EFINITION

Autologous blood sample that has a platelet concentration above hat contained in normal baseline blood plasma.

Platelets contain over 30 bioactive proteins, many of which have a undamental role in tissue healing.





WHAT DEFINES CLINICAL PRP

Normal

200,000/microliter



For Bone/Soft Tissue Enhancement


- 1,000,000 platelets/microliter
- Equals 1 billion platelets per millilite
- So typical 5 ml treatment = 5 billior platelets.

GROWTH FACTORS IN PR

latelet Growth Factor Type	Growth factor Source	Biological Actions
latelet derived growth actor (a-b)	Platelets, osteoblasts, endothelial cells, macrophages, monocytes, smooth muscle cells	Mitogenic for mesenchymal celss and osteoblasts, stimula chemotaxis and mitogenesis in fibroblast/glial/smooth muscle regulates collagenase secretion and collagen synthesis, stimu macrophage and neutrophil chemotaxis
ransforming growth factor GF(alpha –beta)	Platelets, extracellular matrix of bone, cartilage matrix, activated TH1 cells and natural killer cells, macrophages/monocytes and neutrophils	Stimulates undifferented mesenchymal cell proliferation; reg endothelial, fibroblastic and osteoblastic mitogenesis; regulates collagen synthesis and collagenase secretion, regulates mitogenesis of growth factors, stimulate endothelial chemotaxix angiogenesis, inhibits macrophage and lymphocyte prolifera
ascular endothelial growth actor, VEGF	Platelets, endothelial cells	Increases angiogenesis and vessel permeability, stimulate mitogenesis for endothelial cells
pidermal growth factor, GF	Platelets, macrophages, monocytes	Stimulates endothelial chemotaxis / angiogenesis, regulat collagenase secretion, stimulates epithelial /mesenchymal mito
ibroblast growth factor, GF	Platelets, macrophages, mesenchymal cells, chondrocytes, osteoblasts	Promotes growth and differentiation of chondrocytes and osteo mitogenic for mesenchymal cells, chondrocytes and osteobl
onnective tissue growth actor CTGF	Platelets through endocytosis from extracellular environment in bone marrow	Promotes angiogenesis, cartilage regeneration, fibrosis and p adhesion
nsulin like growth factor – IGF -1	Plasma, epithelial cells, endothelial cells, fibroblasts, smooth muscle cells, osteoblasts, bone matrix	Chemotaxis for fibroblasts and stimulates protein synthes enchances bone formation by proliferation and differentiation osteoblasts

PRP ACTIVATION

Activation causes granules to fuse to cell membrane (degranulation)



Proteins/Growth Factors become bioactive (PDGF TGF-B, et) and secreted. Over 95% are secreted within ONE hour.




y bind to

oblasts,

blasts, etc

et cells, like

This leads to intracellular activation creating gene sequencing to direct cellular proliferation, collagen synthesis, etc to provoke tissue repair and tissue regeneration.




PRP PREPARATIOI

- Blood collection with anticoagular
- 1st spin separates whole blood into layers.

RBC's at bottom – we don't want these. Studies show blood in joints can lead to degenerative changes. Synovial fluid treated with RBC's results in cell death.






L TRAINING

PRP PREPARATIOI

Buffy coat is rich in WBC's and platelets.

There are five major types of white bloc


- neutrophils.
- lymphocytes.
- eosinophils.
- monocytes.
- basophils.



PRP PREPARATIOI

Top layer has plasma – water, proteins, electrolyes





PRP PREPARATIOI

If you're just going to do a single spin, you would use the middle layer – buffy coat.

This has a LOT of leucocytes and platelets. So it will be a leucocyte rich (LR) PRP.




PROCESS OF PRP THERAPY



Collect blood



Spin down the blood



Extract platelet-rich plasma




Inject injured area with PRP

Copyright Complete Med Car



SECOND SPII



- The top and middle layers get transferred out.
- Don't want RBC's.
- This creates an upper portion of platelet poor plasma and a bottor layer of platelets with a few RBC's.





YOU WANT MONOCYTES, NOT GRANULOCYTES

UNANSWERED QUESTION



- To activate or not?
- Optimal type of PRP to use?
- PRP alone or with stem cells/exosomes?



Musculoskelet Med (2018) 11:624-634

Otam

Commercially available PRP systems and their PRP preparations

	Company	Blood volume required (mL)	Concentrated volume produced (mL)	Processing time (min)	PPP produced?	Increase in [platelets] (times baseline)
rte-rich PRP						
l	Arthrex	52 [6]	$1-20^{a}$	17 [6]	+	10 ^a
sisCS	EmCyte	54 [6]	6 [6]	10 [6]	+	4–7 [6]
Ш	Biomet	54 [6]	6 [6]	15 [6]	+	3–10 [6]
llan	Isto Biologics/Arteriocyte	52 [6]	3.5–7 [6]	17 [6]	+	3–15 [6]
PReP 2	Harvest	54 [6]	7 [6]	14 [6]	+	5–9 [6]
te-poor PRP						
ogous conditioned a (ACP)	Arthrex	11 [7]	4 [7]	5 [7]	_	1.3 [7]
de						
	Harvest	54 ^a	6.5 ^a	18 ^a	+	3-0
PRP	EmCyte	50 ^a	6.5 ^a	8.5ª	+	4–7 ^a

WHY WE OFFER EMCYTE ANI PUREPR

Offers upwards of 9 billion platelets in a 7ml sample.

L TRAINING

Great control of neutrophils – they are the most abundant eukocyte and show up quickly at injury site. Normally they are cleared quickly by macrophages. If not, they die and release ALL their proinflammatory contents.

Monocytes – largest of leukocytes and are non-inflammatory. The PurePRP system enhances the immune reponse with monocytes in higher concentrations, while allowing providers to control the neutrophil counts.



DOES AGE AFFECT PRP QUALITY



NO!

 A study by Weibrich et al (2004) showed no significant changes in platelet concentration or growth factors in relation to age or gende




INDICATIONS

Soft Tissue

- Achilles
- Plantar Fasciitis
- Rotator Cuff
- Elbow
- Greater Trochanter

- Joints
 - Knee
 - Hip
 - Spine
 - TMJ





ACHILLE

Platelet-Rich Plasma Injection for Chronic Achilles Tendinopathy A Randomized Controlled Trial

JAMA study. 54 randomized pts age 18-70

Conclusion Among patients with chronic mid portion Achilles endinopathy who were treated with eccentric exercises, a PRP njection compared with a saline njection did not result in greater mprovement in pain and activity.



PLANTAR FASCIITIS

s Platelet-rich Plasma Injection more Effective than Steroid Injection in the Treatment of Chronic Plantar Fasciitis in Achieving Long-term Relief?

Malaysian Orthopedic Journal 2019 60 patients, randomized, blinded



Table II: Mean VAS score in both groups

VAS	Group A (PRP)	Group B (Steroid)	P value (at end of 6 months follow-up)
Pre-Treatment	7.137	7.214	
6 Weeks	2.62	1.928	
3 Months	1.931	2.89	
6 Months	1.413	3.785	<0.001

ROTATOR CUF

Nonoperative Treatment of Rotator Cuff Disease With Platelet-Rich Plasma: A Systematic Review of Randomized Controlled Trials

May 2019 Journal of Arthroscopy

ooked at 5 studies, over 200 patients.

The currently limited available evidence on PRP for nonoperative reatment of chronic rotator cuff disease suggests that in the short term, PRP injections **may not be beneficial**. When directly compared with exercise therapy, PRP **does not result** in superior functional outcomes, pain scores, or range of motion.



ATELLAR TENDINOPATHY (JUMPER'S KNEE)

Liddle et al – 81% of patients eturned to pre-symptom levels of activity.

Zayni et al showed better pain relief and function with 2 injections versus one.


PRP appears to be a viable reatment option for chronic efractory patellar tendinopathy, and leukocyte-rich preparation is ecommended. (ONE SPIN)



LATERAL EPICONDYLITIS (TENNI ELBOW

Meta- analysis showed PRP was better at reducing pain in short and ong term versus steroid. Effects asted up to 2 years. No subcutaneous atrophy.

One of the best studies (Mishra et al) showed leucocyte rich yielded better long term results than idocaine or dry needling.



ELBOW LIGAMENT PARTIAL TEA

Podesta et al. followed the progress of 34 throwing athletes being reated for partial thickness tears of the UCL with a single PRP injection [56].

They found that 30 of the 34 athletes were able to return to the same level of play or higher at an average of 12 weeks



HOHEI OHTANI

While UCL injuries can lead to formmy John surgery, several pitchers -- including New York Yankees right-hander Masahiro Tanaka and Boston Red Sox left-hander Chris Sale -- have had PRP njection therapy as a more conservative treatment and continued to pitch without further ssues.

For Ohtani – he still ended up needing the surgery.






GREATER TROCHANTERIC BURSITI

Platelet-Rich Plasma Versus Surgery for the Management of Recalcitrant Greater Trochanteric Pain Syndrome: A Systematic Review

March 2020 Journal of Arthroscopy Santiago et al.

10 studies evaluated. 210 patients. F/U over 2 years plus.

PRP outcome was equivalent to surgery (awesome), but quite a few complications with surgery (retears, DVT, wound issues, snapping hip).



y design characteristics for PRP versus control injection for osteoarthritis

				Sample size				Intervention/injection volume and contents			
	Study	Year of publication	Level of evidence	PRP	Control	Type of PRP	Number of injections	PRP	Control	Follow- (months	
S	Battaglia et al. [72]	2013	I	50	50	LR-PRP	3	5 mL PRP	30 mg HA	12	
S	Dallari et al. [73]	2016	I	44, +HA: 31	36	NR	3	7 mL PRP + HA	30 mg HA	12	
S	Doria et al.[74]	2017	II	40	40	NR	3	5 mL PRP	15 mg HA	12	
S	Sante et al. [75]	2016	I	21	22	NR	3	3 mL PRP	30 mg HA	4	
itis	Cole et al. [76]	2017	I	49	50	LP-PRP	3	4 mL PRP	16 mg HA injection	12	
itis	Duymus et al. [77]	2017	I	41	HA: 40, ozone: 39	NR	2	5 mL PRP	40 mg HA, 15 mL ozone	12	
itis	Gormeli et al. [78]	2017	I	PRP (3×): 46, PRP (1×): 45	HA: 46, placebo: 45	NR	3 versus 1	5 mL PRP	30 mg HA, NR saline	6	
itis	Lana et al. [79]	2016	I	36, +HA: 33	36	NR	3	5 mL PRP + 20 mg HA	20 mg HA	12	
itis	Montanez et al. [80]	2016	I	28	27	NR	3	NR	NR HA	6	
itis	Paterson et al. [81]	2016	I	12	11	MD	3	3 mL PRP	3 mL HA	3	
itis	Simental et al. [82]	2016	I	33	32	LP-PRP	3	3 mL PRP	Tylenol 500 mg q8h	4 (<	
itis	Smith et al. [83•]	2016	I	15	15	Lr-rrr	3	3-8 mL PRP	3–8 mL saline	12	

d, LP-PRP leukocyte-poor PRP, LR-PRP leukocyte-rich PRP, PRGF plasma rich in growth factors, HA hyaluronic acid

= 2/4 positive. Knee = 7/8 positive

KNEE O

The temporal effect of platelet-rich plasma on pain and physical function in the treatment of knee esteoarthritis: systematic review and meta-analysis of randomized controlled trials

Journal of Ortho Surgery & Research 2017

Reviewed 14 studies and 1400 patients.

• Intra-articular PRP injections probably are **more efficacious** in the treatment of knee OA in terms of pain relief and self-reported function improvement at 3, 6 and 12 months follow-up, compared with other injections, including salir placebo, HA, ozone, and corticosteroids.

ONE INJECTION OR MULTIPLE

Single- and double-dose of clatelet-rich clasma versus hyaluronic acid for reatment of knee osteoarthritis: A candomized controlled trial.

World J Orthop. 2019

95 patients for 4 months.

Found that the efficacy of PRP increases after multiple injections (3 wks apart).



GENERATIVE DISC DISEASE

reatment of symptomatic degenerative intervert ebral discs with autologous platelettich plasma: follow-up at 5-9 years.

Regen Med. 2019

This subset of patients demonstrated statistically and clinically significant mprovements in pain and function at 5-9 years postinjection.



JMBAR FACET YNDROME

Analysis of the clinical efficacy of platelet-rich plasma therapy in the reatment of patients with solated facet-syndrome of the umbar spine

Russian study – 49 pts followed 18 months.

Clinical efficacy is confirmed by the persistent significant reduction of pain symptoms and restoration of unctional status in the early and ate postoperative periods with low isks of adverse outcomes.



latelet-rich plasma for the nerapeutic management of emporomandibular joint isorders: a systematic review.

ooked at 6 studies, published 018 in J Oral Maxillofac Surg.

our of the studies bund PRP injections to be uperior in terms of approvements in mandibular ange of motion and pain tensity up to 12 months after eatment, while the emaining two studies found milar results for the different eatments.



CONCLUSIO

PRP – Very Low Risk and relatively nexpensive.

ots of unanswered questions

- Dosing we have an idea.
- Activation
- LR or LP

No gold standard.

Many positive studies despite this!

Great option, anecdotally great with stem cells/exosomes.

